Patent ID: 7485314

Claim:
A method of decreasing an antibody response to an administered soluble lysosomal enzyme in a mammalian host, comprising the steps of: (a) administering to the mammalian host for at least about two weeks effective amounts of (i) cyclosporine A and (ii) azathioprine, wherein the cyclosporine A is maintained at a trough blood level of at least 200 ng/ml, and wherein the azathioprine is administered at a dose from 2.5 to 5 mg/kg/day; (b) after step (a), administering to the mammalian host for at least about two weeks effective amounts of (i) cyclosporine A, (ii) azathioprine, and (iii) a soluble lysosomal enzyme naturally comprising or conjugated to a mannose-6-phosphate high uptake moiety, wherein the cyclosporine A is maintained at a trough blood level of at least 200 ng/ml, and wherein the azathioprine is administered at a dose from 2.5 to 5 mg/kg/day, (c) after step (b), discontinuing administration of cyclosporine A and azathioprine, and (d) after step (c), administering said soluble lysosomal enzyme, wherein during step (d) the mammalian host exhibits an antibody titer to said soluble lysosomal enzyme in the absence of continued immune suppression that is decreased compared to the antibody titer induced by said lysosomal enzyme in a mammalian host that has not undergone steps (a)-(c).